Wai Chun Bio-Technology Limited (WAI CHUN BIOTEC) has filed its Monthly Return for the period ended 31 August 2026, showing no change in either authorised or issued share capital during the month.

Authorised and Issued Capital • Authorised share capital held steady at 10.00 billion ordinary shares and 204.00 million convertible preference shares, together representing HKD 102.04 million at HKD 0.01 par value per share. • Issued ordinary shares remained unchanged at 384.31 million. The company held no treasury shares. • Management confirmed compliance with the Hong Kong Stock Exchange’s minimum 25% public-float requirement.

Equity-linked Instruments • Share options: 15.95 million options (exercise price HKD 0.25, expiring 26 June 2030) were outstanding; no options were exercised in August. • Convertible bonds: HKD 102.05 million of principal remains outstanding across four tranches, convertible at HKD 0.06–0.07 per share. Full conversion would permit issuance of up to 1.67 billion new ordinary shares. Maturities run to 2027 for three tranches and 2028 for the most recent HKD 15.00 million tranche approved on 17 September 2025.

Other Matters • The company reported no warrants, no additional share agreements, no treasury share movements, and no Hong Kong Depositary Receipts during the month. • All securities-related actions undertaken in August were confirmed to comply with Hong Kong listing rules and relevant legal requirements.

Conclusion WAI CHUN BIOTEC’s equity structure was unchanged in August 2026, with stable issued capital and sufficient public float. Potential dilution remains concentrated in the existing HKD 102.05 million convertible bond portfolio and 15.95 million outstanding share options.